Becton, Dickinson and Company to Offer Senior Unsecured Notes

FRANKLIN LAKES, N.J., Dec. 4, 2014 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) ("BD") announced today its intention to offer senior unsecured notes under a shelf registration statement on Form S-3 (File No. 333-183059) on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.

BD intends to use the net proceeds from the offering, together with borrowings under its commercial paper program, borrowings under a new term loan facility, and cash on hand, to finance the acquisition of CareFusion Corporation and to pay related fees and expenses.

Goldman, Sachs & Co. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering. A shelf registration statement relating to the offering was filed with the Securities and Exchange Commission on August 3, 2012. A preliminary prospectus supplement and the accompanying base prospectus relating to the offering have been filed with the Securities and Exchange Commission and are available on its website, Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from:

Goldman, Sachs & Co.

J.P. Morgan Securities LLC

200 West Street

383 Madison Ave. 

New York, NY 10282

New York, NY 10179

Attn: Prospectus Department

Attn: Investment Grade Syndicate Desk


(212) 834-4533

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BD

BD is a leading medical technology company that partners with customers and stakeholders to address the world's evolving health needs. BD's innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.

Ed Cook, Corporate Communications – 201-847-7176
Monique Dolecki, Investor Relations – 201-847-5378

To view the original version on PR Newswire, visit:

SOURCE BD (Becton, Dickinson and Company)